title: Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe.
abstract: Adalimumab effectiveness on clinical, functional and work-related outcomes was evaluated in patients with active ankylosing spondylitis or psoriatic arthritis treated in routine clinical practice in central-eastern Europe.
  
  
  
  Patients (n = 555) were followed for 12 months. Primary end point was percentage of patients with a treatment response (≥50% decrease from baseline in Bath Ankylosing Spondylitis Disease Activity Index or ≥1.2 point decrease from baseline in Disease Activity Index-28 joint for axial or peripheral symptoms, respectively). Functional status was evaluated by the Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire Disability Index. Working ability was evaluated by the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem.
  
  
  
  76.1% of patients with axial symptoms and 83.5% with peripheral symptoms achieved a treatment response. Frequency of extra-articular manifestations decreased. Improvements were observed in functional status and workability. No new safety signals were observed.
  
  
  
  Adalimumab was effective and well tolerated during real-world use in central-eastern Europe.
authors.affiliation: Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
authors.forename: Sándor
authors.initials: S
authors.lastname: Szántó
authors.affiliation: National Institute of Rheumatology & Physiotherapy, Budapest, Hungary.
authors.forename: Gyula
authors.initials: G
authors.lastname: Poór
authors.affiliation: "Sf. Maria" Clinical Hospital, Bucharest, Romania.
authors.forename: Daniela
authors.initials: D
authors.lastname: Opris
authors.affiliation: National Medical University, Kyiv, Ukraine.
authors.forename: Oleg
authors.initials: O
authors.lastname: Iaremenko
authors.affiliation: Rheumatology Division, 2nd Department of Internal Medicine, St Anne's University Hospital Brno, Brno, Czech Republic.
authors.forename: Leona
authors.initials: L
authors.lastname: Procházková
authors.affiliation: Tartu University Hospital, Tartu, Estonia.
authors.forename: Reet
authors.initials: R
authors.lastname: Kuuse
authors.affiliation: AbbVie Ltd, Budapest, Hungary.
authors.forename: Orsolya
authors.initials: O
authors.lastname: Nagy
authors.affiliation: AbbVie Biopharmaceuticals GmbH, Minsk, Belarus.
authors.forename: Valentyn
authors.initials: V
authors.lastname: Chernyshov
authors.affiliation: Hospitaller Brothers of St John of God Hospital, Budapest, Hungary.
authors.forename: Pál
authors.initials: P
authors.lastname: Géher
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D005060:Europe; D005061:Europe, Eastern; D005500:Follow-Up Studies; D006801:Humans; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab
keywords: adalimumab; ankylosing spondylitis; extra-articular manifestations; observational study; psoriatic arthritis; workability